Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
NCT04150029 · Novartis Pharmaceuticals · PHASE2 · terminated · last registry update 2026-01-13 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Novartis made a decision to early terminate the sabatolimab clinical development program, including the CMBG453C12201 trial, following the negative results from other 2 trials.” | Open Targets' class: another study, business administrative | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HAVCR2 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-10-16Also stopped (terminated): Novartis Pharmaceuticals, Sabatolimab + Azacitidine (NCT04623216)
- 2025-10-10Also stopped (terminated): Novartis Pharmaceuticals, HDM201 + MBG453 (NCT03940352)
- 2025-06-03Results posted on the registry: Novartis Pharmaceuticals, Sabatolimab + Azacitidine (NCT04623216)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision